Stocks›Healthcare›BRTX

BRTX Biorestorative Therapies, Inc.

NasdaqResearch view

Biorestorative Therapies, Inc. operates in the Services-Misc Health & Allied Services, Nec industry.

$1.54+5.48%
Oct 16 close · 1D EOD · Databento
HealthcareServices-Misc Health & Allied Services, NecMicro-capSEC EDGAR FY 2025-12-31

On the WireNo stories on BRTX yet. Follow the company and the next one lands in Following.

The numbers · FY2025, filed

SEC EDGAR
Market cap$39M
Revenue$359,700−10.30%
Net income$-14.2M
EPS, diluted$-1.58−36.20%
Gross margin93.4%
Operating margin-4350.1%
All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31
SectorHealthcare
Market Cap$39.2M
Enterprise Value$38.0M
Income$-14.2M
Sales$359,700
Book/sh$0.01
Cash/sh$0.06
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio0.84
Current Ratio0.84
Debt/Eq0.70
EPS (ttm)$-1.58
EPS this Y-36.2%
EPS past 3/5Y—
Sales past 3/5Y44.3%
EPS Y/Y TTM-36.2%
Sales Y/Y TTM-10.3%
Shs Outstand25.48M
ROA-349.1%
ROE-3992.2%
ROIC—
Gross Margin93.4%
Oper. Margin-4350.1%
Profit Margin-3959.4%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$46,000
FY21
$119,800
FY22
$145,800
FY23
$401,000
FY24
$359,700
FY25

Operating leverage — margins

GrossOperatingNet
0%55%110%93%-4350%-3959%FY21FY22FY23FY24FY25
Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it
USDFY2021FY2022FY2023FY2024FY2025

Same industry

In the screener →

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.